Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD 20892, USA.
Viruses. 2019 Apr 16;11(4):346. doi: 10.3390/v11040346.
Influenza A virions possess two surface glycoproteins-the hemagglutinin (HA) and neuraminidase (NA)-which exert opposite functions. HA attaches virions to cells by binding to terminal sialic acid residues on glycoproteins/glycolipids to initiate the infectious cycle, while NA cleaves terminal sialic acids, releasing virions to complete the infectious cycle. Antibodies specific for HA or NA can protect experimental animals from IAV pathogenesis and drive antigenic variation in their target epitopes that impairs vaccine effectiveness in humans. Here, we review progress in understanding HA/NA co-evolution as each acquires epistatic mutations to restore viral fitness to mutants selected in the other protein by host innate or adaptive immune pressure. We also discuss recent exciting findings that antibodies to HA can function in vivo by blocking NA enzyme activity to prevent nascent virion release and enhance Fc receptor-based activation of innate immune cells.
甲型流感病毒粒子拥有两种表面糖蛋白——血凝素(HA)和神经氨酸酶(NA)——它们发挥着相反的作用。HA 通过与糖蛋白/糖脂上的末端唾液酸残基结合将病毒粒子附着到细胞上,从而启动感染周期,而 NA 则切割末端唾液酸,释放病毒粒子以完成感染周期。针对 HA 或 NA 的抗体可以保护实验动物免受 IAV 发病机制的影响,并在其靶表位上驱动抗原变异,从而降低疫苗在人类中的有效性。在这里,我们回顾了对 HA/NA 共同进化的理解进展,因为每种蛋白都会获得上位突变,以恢复在另一种蛋白中被宿主固有或适应性免疫压力选择的突变体的病毒适应性。我们还讨论了最近令人兴奋的发现,即针对 HA 的抗体可以通过阻断 NA 酶活性在体内发挥作用,从而阻止新形成的病毒粒子释放,并增强基于 Fc 受体的先天免疫细胞激活。